Epigenomics

In Brief This Week: PerkinElmer, OraSure Technologies, LabCorp, Molzym, UniLabs, and More

Epigenomics Reports 24 Percent Drop in 2020 Revenues, Seeks Sale After Negative Coverage Decision

CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon

Epigenomics Issues €5.5M Convertible Bond

Epigenomics Posts 30 Percent Rise in Q3 Revenues

Epigenomics Q2 Revenues Slide 76 Percent on Coronavirus Challenges

Epigenomics Q1 Revenues Down 28 Percent

Epigenomics Preliminary Q1 Revenues Drop 33 Percent

In Brief This Week: Vermillion, Todos Medical, Genomics Medicine Ireland, and More

CMS Seeks Public Input on Epigenomics' National Coverage Request for Colon Cancer Screening Test

Epigenomics Posts 69 Percent Drop in Q3 Revenues

Epigenomics Q2 Revenues Slide 25 Percent

Epigenomics Q1 Revenues Rise 7 Percent

Epigenomics 2018 Revenues Down 21 Percent

BioChain Threatens Legal Action Against Epigenomics for Contract Termination

Epigenomics Terminates BioChain Licensing Deal; Provides 2019 Revenue Outlook

In Brief This Week: Seegene, Epigenomics, Qiagen, and More

Epigenomics Posts 57 Percent Rise in Q3 Revenues